Clinical Trials Logo

Dry Eye clinical trials

View clinical trials related to Dry Eye.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06443775 Recruiting - Dry Eye Clinical Trials

An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

Start date: June 17, 2024
Phase:
Study type: Observational

Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) in adult participants with dry eye symptoms and who are high digital device users. NGE-UD is an over-the-counter (OTC) monograph drug indicated for the temporary relief of symptoms of eye dryness. Participants will administer 1 drop of NGE-UD on Day 1 for the acute phase of the study, after Day 1 participants will administer 1-2 eye drops in each eye at least twice a day but as much as needed through Day 15. Around 50 adult participants will be enrolled at one site in the United States. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site as per standard of care.

NCT ID: NCT06439394 Recruiting - Dry Eye Clinical Trials

An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

Start date: May 31, 2024
Phase:
Study type: Observational

Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate real-world experiences with Optive MEGA-3 (OM3) on relieving dry eye symptoms in adult participants with DED. OM3 is an over the counter (OTC) monograph drug indicated for the temporary relief of symptoms of eye dryness. Participants will administer 1 drop of OM3 on Day 1 for the acute phase of the study, then participants will administer 1-2 eye drops in each eye at least twice a day but as much as needed through Day 15. Around 50 adult participants will be enrolled at one site in the United States. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site as per standard of care.

NCT ID: NCT06427031 Recruiting - Dry Eye Clinical Trials

Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients

Start date: July 14, 2023
Phase: Phase 3
Study type: Interventional

In patients with dry eye syndrome, the test drug(TJO-083) or the control drug is administered for 12 weeks, and the corneal staining of each group would be evaluated. The purpose of this clinical Study is to demonstrate that the test drug is not clinically inferior to the control drug.

NCT ID: NCT06411132 Recruiting - Dry Eye Clinical Trials

Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye

GEMINAE
Start date: March 15, 2024
Phase:
Study type: Observational

Primary Objective - To assess the proportion of patients with Sjögren's dry eye who demonstrate impaired corneal sensitivity. Secondary Objectives - To assess corneal sensitivity via Cochet-Bonnet esthesiometer. - To assess tear secretion via Schirmer I test. - To assess OPAS questionnaire results.

NCT ID: NCT06392438 Recruiting - Dry Eye Clinical Trials

Cyclosporine and Intense Pulsed Light for Dry Eye in Contact Lens Users

CycliP
Start date: April 25, 2024
Phase: Phase 3
Study type: Interventional

In this study, two treatments typically used for dry eye disease will be tried for contact lens users to see if their symptoms when they use their contact lenses get better. Cyclosporine is a drop that is used for long-term management of the inflammation and Intense pulsed light (IPL) is a treatment done in a clinic to improve the health of the eyelid glands. The main question in this study is: Does the combined treatment of cyclosporine and IPL improve the symptoms and the dry eye signs of contact lens wearers? All the participants will receive the cyclosporine drops for 4 months twice a day. The research team will split the group of participants in two, half receiving the real IPL treatment and half receiving a sham IPL treatment during the last two months of the study. This will allow to compare the two groups to see how IPL helped. The dry eye tests will be done at the start of the study, after two months and after 4 months. The tests will include a dry eye symptoms questionnaire, measures on the tears, the structures of the front of the eye and the eyelids.

NCT ID: NCT06346340 Recruiting - Dry Eye Clinical Trials

A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy

Start date: April 30, 2024
Phase: Phase 4
Study type: Interventional

A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy

NCT ID: NCT06324890 Recruiting - Dry Eye Clinical Trials

PET-CT Imaging Features of Meibomian Glands

Start date: January 31, 2024
Phase:
Study type: Observational

Analysis the results of Dry eye analysis results and PET-CT imaging comprehensively

NCT ID: NCT06296966 Recruiting - Dry Eye Clinical Trials

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Start date: February 29, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.

NCT ID: NCT06287879 Recruiting - Dry Eye Clinical Trials

Function and Morphological Characteristics of Meibomian Gland in Patients With Renal Anemia

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Renal anemia refers to anemia in which the absolute or relative production of erythropoietin (EPO) is insufficient due to various kidney diseases, and uremic toxins affect erythropoietin production and its lifespan. Common treatment drugs for renal anemia include erythropoietin EPO and Roxadustat (FG-4592). Medical history information was collected from patients with renal anemia who visited the ophthalmology department with dry eye symptoms. This study will help to determine the function and morphological characteristics of meibomian gland in patients with renal anemia

NCT ID: NCT06245421 Recruiting - Dry Eye Clinical Trials

Evaluation of the Efficacy and Safety of DM934 Versus Théalose on Eye Dryness

Start date: March 7, 2024
Phase: N/A
Study type: Interventional

This study is a multicentric, comparative, randomized, investigator-blinded, parallel group study to demonstrate the non-inferiority of DM934 in comparison with Théalose in terms of cornea and conjunctiva staining (Oxford score) on patients with moderate to severe ocular dryness, after 35 days of treatment